---
layout: default
title: Alpha Lipoic Acid Arnica Montana Whole Coenzyme A 
parent: 僅模型預測 (L5)
nav_order: 265
evidence_level: L5
indication_count: 0
---

# Alpha Lipoic Acid Arnica Montana Whole Coenzyme A 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alpha Lipoic Acid / Arnica Montana / Sus Scrofa Complex: Insufficient Data — No Repurposing Predictions Generated

## One-Sentence Summary

This submission covers a 15-ingredient complex combining antioxidants (Alpha Lipoic Acid, Coenzyme A, NADIDE), homeopathic botanicals (Arnica Montana, Sanguinaria Canadensis, Solanum Dulcamara, Toxicodendron Pubescens), biological porcine extracts (Sus Scrofa Cartilage, Embryo, Placenta, Umbilical Cord), and mineral components (Sulfur, Silicon Dioxide).
The TxGNN model returned **no predicted indications** for this compound, and it has **no US market authorization**, leaving the repurposing evaluation without a viable candidate target.
Without an established original indication or model output, a formal evidence review cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on file |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — No predictions generated |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why Could TxGNN Not Generate Predictions?

TxGNN operates by matching a drug's DrugBank identifier against its knowledge graph, then ranking candidate disease nodes by predicted biological proximity. This pipeline could not be completed for three compounding reasons:

**1. No DrugBank ID.** The compound has no DrugBank entry as a unified entity. TxGNN requires a single DrugBank node as the query anchor. A 15-ingredient formulation — particularly one blending homeopathic dilutions (Arnica Montana, Sulfur, Toxicodendron Pubescens at unspecified potencies), metabolic cofactors (Coenzyme A, NADIDE, Alpha Lipoic Acid), and porcine biologics (Sus Scrofa Embryo, Placenta, Umbilical Cord) — does not map to any single node in the knowledge graph.

**2. No established original indication.** Without a known approved indication, there is no reference phenotype against which mechanistic similarity to new indications can be benchmarked.

**3. Mixed ingredient categories.** The formulation blends conventional biochemical agents (Alpha Lipoic Acid is a well-characterised antioxidant; NADIDE is NAD⁺; Coenzyme A is a metabolic cofactor) with homeopathic substances at dilution levels that may not carry pharmacological activity in the classical sense. This categorical ambiguity prevents reliable knowledge-graph traversal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this compound as a combination entity.

> **Note:** Individual ingredients such as Alpha Lipoic Acid and Coenzyme A have independent clinical trial records, but these do not apply to this multi-ingredient formulation and cannot be attributed here.

---

## Literature Evidence

Currently no related literature available for this specific combination.

---

## US Market Information

This compound has no US FDA authorization. No NDA, BLA, or OTC monograph registration was identified for the 15-ingredient combination.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** No DDI records were returned. Key warnings and contraindications are flagged as data gaps. Given the presence of **Toxicodendron Pubescens** (poison oak) and **Sanguinaria Canadensis** (bloodroot) — both with known toxicity profiles at non-homeopathic concentrations — a full safety review should be prioritised before any clinical use consideration.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN returned no predictions because this compound lacks a DrugBank identifier and an established original indication; the heterogeneous nature of the 15 ingredients (homeopathic botanicals, porcine biologics, metabolic cofactors, and inert excipients) cannot be resolved to a single knowledge-graph node, making model-based repurposing evaluation infeasible in its current form.

**To proceed, the following is needed:**

- **Ingredient disambiguation:** Determine whether each active ingredient is present at pharmacologically meaningful concentrations or at homeopathic dilutions (e.g., 6X, 30C). This determines which regulatory pathway applies (drug vs. homeopathic remedy vs. biologic).
- **Lead ingredient selection:** Identify which ingredient(s) carry the primary therapeutic hypothesis, and evaluate those individually through TxGNN using their respective DrugBank IDs.
- **Original indication documentation:** Obtain the product's labelled indication (if any) from the manufacturer or a non-US jurisdiction where it may be authorised.
- **Safety data package:** Retrieve prescribing information or safety monograph, prioritising data on Toxicodendron Pubescens and Sanguinaria Canadensis given their known toxicity.
- **TFDA/package insert retrieval (DG001):** Download and parse the product monograph PDF if a foreign regulatory filing exists.
- **DrugBank query per ingredient (DG002):** Query DrugBank individually for Alpha Lipoic Acid, NADIDE, and Coenzyme A to establish MOA baselines for the biochemical components.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

